Develops and sells medical devices used by physicians and other medical professionals to diagnose and treat cardiovascular, digestive, neurological and urological conditions.
10-K for FY2025, filed Feb 17, 2026
Interventional Cardiology & Vascular Therapies is the largest business; U.S. customers typically pay for devices within 30 days. Consigned products count as sold when used or implanted, while some heart-monitoring services are paid over the service period.
10-K for FY2025, filed Feb 17, 2026
10-K for FY2025, filed Feb 17, 2026
FY2025 revenue by product or service ↗$20.1B
10-K for FY2025, filed Feb 17, 2026
$20.1B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Endoscopy
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
15%
FY2022: 18%
|
Endoscopy, FY2025
$2.9B Sources
|
Sold outright |
|
Urology
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
14%
FY2022: 14%
|
Urology, FY2025
$2.7B Sources
|
Sold outright |
|
Neuromodulation
Sold outright
|
6.0%
FY2022: 7.2%
|
Neuromodulation, FY2025
$1.2B Sources
|
Sold outright |
|
Interventional Cardiology & Vascular Therapies
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
23% |
Interventional Cardiology & Vascular Therapies, FY2025
$4.6B Sources
|
Sold outright |
|
Watchman
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
9.8%
FY2022: 8.0%
|
Watchman, FY2025
$2B Sources
|
Sold outright |
|
Electrophysiology
Sold outright
10-K for FY2025, filed Feb 17, 2026 |
17%
FY2022: 4.6%
|
Electrophysiology, FY2025
$3.3B Sources
|
Sold outright |
|
Cardiac Rhythm Management
Mix
10-K for FY2025, filed Feb 17, 2026 |
12%
FY2022: 17%
|
Cardiac Rhythm Management, FY2025
$2.3B Sources
|
Mix |
|
Interventional Oncology & Embolization
Sold outright
|
5.0% |
Interventional Oncology & Embolization, FY2025
$996M Sources
|
Sold outright |
It sells devices to hospitals, clinics, outpatient facilities and medical offices, mainly through direct sales teams; distributors and dealers serve some international markets. Group purchasing organizations, hospital networks and other buying groups also represent a substantial part of sales.
10-K for FY2025, filed Feb 17, 2026
Yes. It kept 14 cents of every revenue dollar as net income in FY2025 and turned 18 cents into free cash flow.
8-K, filed Aug 26, 2026
On August 25, 2026, Boston Scientific Corporation (the “Company”) identified a cybersecurity incident affecting certain of its information…View ↗
8-K, filed May 18, 2026
On May 18, 2026, Boston Scientific Corporation (the “Company”) issued a press release announcing that the Company has entered into an…View ↗
Growing. Revenue grew 69% in 4 years, from $11.9B in FY2021 to $20.1B in FY2025, about 14% a year.
Pulsed-field ablation gains prominence
The earlier report listed FARAPULSE pulsed-field ablation among several electrophysiology products; the latest says it has become the unit’s predominant product and revenue component.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 17, 2026Rhythmia™ Mapping Systems, catheter-based, 3-D cardiac mapping and navigation solutions designed to help diagnose and guide treatment of a…View ↗
Since the launch of the FARAPULSE™ PFA System in 2024, we have observed rapid conversion from legacy treatment modalities to PFA. It is now…View ↗
Loading...